Page last updated: 2024-10-31

metoprolol and Cytokine Release Syndrome

metoprolol has been researched along with Cytokine Release Syndrome in 1 studies

Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.

Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Yang, Y1
Zhang, Y1
Xing, X1
Xu, G1
Lin, X1
Wang, Y1
Chen, M1
Wang, C1
Zhang, B1
Han, W1
Hu, X1

Other Studies

1 other study available for metoprolol and Cytokine Release Syndrome

ArticleYear
IL-6 translation is a therapeutic target of human cytokine release syndrome.
    The Journal of experimental medicine, 2023, 11-06, Volume: 220, Issue:11

    Topics: Cytokine Release Syndrome; Cytokines; Humans; Immunotherapy, Adoptive; Interleukin-6; Metoprolol; Re

2023